sodium 3'-{[(cyclopentylcarbonyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate | 868554-20-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: sodium 3'-{[(cyclopentylcarbonyl)(3-phenylpropyl)amino]methyl}-1,1'-biphenyl-4-carboxylate
• 英文别名: Sodium;4-[3-[[cyclopentanecarbonyl(3-phenylpropyl)amino]methyl]phenyl]benzoate
• CAS: 868554-20-5
• 化学式: C₂₉H₃₀NO₃*Na
• 分子量: 463.552
• InChiKey: BGQHZRNMUUCJRV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.87
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound
  申请人：Nakade Shinji

  公开号：US20080132574A1

  公开（公告）日：2008-06-05

  [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

  【问题】需要一种选择性结合于BLT2的化合物和预防和/或治疗BLT2介导的疾病，如皮肤病的药物。 【解决方法】本发明提供具有BLT2结合活性的化合物，其盐，溶剂化物或前药。由于具有BLT2结合活性的化合物，特别是由式（I）表示的化合物，其盐，溶剂化物或前药（式中的符号与说明书具有相同的含义）具有BLT2结合活性，因此对于预防和/或治疗BLT2介导的疾病，例如皮肤病，肠道疾病，HIV感染，获得性免疫缺陷综合症，移植排斥，移植物排斥，移植物抗宿主病，自身免疫性疾病，过敏性疾病，炎症，感染，溃疡，淋巴瘤，恶性肿瘤，白血病，动脉硬化，肝炎，肝硬化或癌症等具有用处。
• NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1745800A1

  公开（公告）日：2007-01-24

  [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) , salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

  [问题]需要选择性结合 BLT2 的化合物和 BLT2 介导的疾病如皮肤病的预防和/或治疗药物。 [解决问题的方法】本发明提供了具有 BLT2 结合活性的化合物、其盐、其溶液或其原药。由于具有 BLT2 结合活性的化合物，特别是由式（I）代表的化合物 式中的符号含义与说明书相同）具有 BLT2 结合活性，因此可用于预防和/或治疗 BLT2 介导的疾病，例如：皮肤病、肠道疾病、溃疡病、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎等、皮肤病、肠道疾病、艾滋病病毒感染、获得性免疫缺陷综合征、移植排斥、移植排斥、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、炎症、感染、溃疡、淋巴瘤、恶性肿瘤、白血病、动脉硬化、肝炎、肝硬化或癌症等。
• Novel BLT2-mediated disease, BLT2-binding agent and compound
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2172222A2

  公开（公告）日：2010-04-07

  [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS] FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) , salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

  [问题] 需要能选择性地与 BLT2 结合的化合物以及预防和/或治疗 BLT2 介导的疾病 （如皮肤病）的药物。 [解决问题的方法］本发明提供了具有 BLT2 结合活性的化合物、其盐、其溶液或其原药。由于具有 BLT2 结合活性的化合物，特别是式 (I) 所代表的化合物 式中的符号含义与说明书相同）具有 BLT2 结合活性，因此可用于预防和/或治疗 BLT2 介导的疾病，例如：皮肤病、肠道疾病、溃疡病、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎、溃疡性结肠炎等、皮肤病、肠道疾病、艾滋病病毒感染、获得性免疫缺陷综合征、移植排斥、移植排斥、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、炎症、感染、溃疡、淋巴瘤、恶性肿瘤、白血病、动脉硬化、肝炎、肝硬化或癌症等。
• US8673889B2
  申请人：——

  公开号：US8673889B2

  公开（公告）日：2014-03-18